These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 12173728)

  • 21. Perinatal outcomes and the use of oral hypoglycemic agents.
    Bertini AM; Silva JC; Taborda W; Becker F; Lemos Bebber FR; Zucco Viesi JM; Aquim G; Engel Ribeiro T
    J Perinat Med; 2005; 33(6):519-23. PubMed ID: 16318615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus.
    Gudat U; Bungert S; Kemmer F; Heinemann L
    Diabet Med; 1998 Mar; 15(3):194-8. PubMed ID: 9545119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study].
    Lundershausen R; Orban S; Pissarek D; Panzram G
    Wien Klin Wochenschr; 1987 Sep; 99(17):603-8. PubMed ID: 3118579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes.
    Juntti-Berggren L; Pigon J; Hellström P; Holst JJ; Efendic S
    Diabetes Nutr Metab; 2000 Feb; 13(1):7-12. PubMed ID: 10824717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes.
    Vray M; Attali JR
    Diabete Metab; 1995 Dec; 21(6):433-9. PubMed ID: 8593925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of acarbose and simultaneous antacid therapy on blood glucose.
    Höpfner M; Durani B; Spengler M; Fölsch UR
    Arzneimittelforschung; 1997 Oct; 47(10):1108-11. PubMed ID: 9368703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
    Hother-Nielsen O; Schmitz O; Andersen PH; Pedersen O; Beck-Nielsen H
    Diabetes Res; 1988 Jun; 8(2):63-70. PubMed ID: 3147830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
    Heuer LJ; Kaufmann HH
    Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial].
    Bachmann W; Lotz N; Mehnert H; Rosak C; Schöffling K
    Dtsch Med Wochenschr; 1988 Apr; 113(16):631-6. PubMed ID: 3129273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes.
    Scheen AJ; Jaminet C; Luyckx AS; Lefebvre PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):70-6. PubMed ID: 3104218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
    Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
    Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
    Brunetti P; Pagano G; Turco C; Gori M; Perriello G;
    Diabetes Nutr Metab; 2004 Dec; 17(6):350-7. PubMed ID: 15887629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
    Abbink EJ; Pickkers P; van Rosendaal AJ; Lutterman JA; Tack CJ; Russel FG; Smits P
    Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.